Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) is close to finalizing a deal worth around $10 billion to acquire Verona Pharma (NASDAQ:VRNA), a biotech firm specializing in lung diseases, according to a report by the Financial Times on Wednesday.
The deal would value Verona at $107
